Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Is The Acquired Immunodeficiency Syndrome (AIDS) Market Size Likely To Evolve From 2025 Through 2034?
The market size for acquired immunodeficiency syndrome (aids) has experienced robust growth in recent years. It is projected to expand from $32.09 billion in 2024 to $33.75 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 5.2%. Historically, this expansion has been driven by factors such as an increase in HIV infection rates, enhanced government investment in HIV treatment, broader global awareness initiatives, advancements in diagnostic capabilities, and increased backing from non-governmental organizations.
The market size for acquired immunodeficiency syndrome (aids) is anticipated to demonstrate robust expansion in the coming years. It is projected to grow to $41.28 billion by 2029, progressing at a compound annual growth rate (CAGR) of 5.2%. This growth over the forecast period can be attributed to several factors, including an increasing demand for long-acting injectable therapies, wider adoption of pre-exposure prophylaxis (PrEP), rising investments in HIV cure research, the expansion of telemedicine services for HIV care, a growing emphasis on personalized medicine, and increasing awareness regarding early HIV diagnosis. Significant trends expected during the forecast period involve a transition towards single-tablet regimens, an increasing preference for injectable and implantable HIV treatments, a rising demand for digital health solutions in HIV management, growing interest in functional HIV cure strategies, and the expanding application of artificial intelligence in drug discovery.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21076&type=smp
Which Industry Drivers Are Expected To Accelerate The Acquired Immunodeficiency Syndrome (AIDS) Market From 2025 To 2029?
The rising incidence of HIV infections is anticipated to stimulate the expansion of the acquired immunodeficiency syndrome (AIDS) market moving forward. HIV infections denote a condition caused by the human immunodeficiency virus (HIV), which targets the immune system, thereby diminishing the body’s capacity to ward off illnesses and diseases. The increased prevalence of HIV infections is attributed to unprotected sexual contact with an infected individual, the sharing of needles or syringes, exposure to contaminated blood products, having multiple sexual partners, and a compromised immune system or pre-existing sexually transmitted infections. Management of acquired immunodeficiency syndrome (AIDS) aids HIV infection patients by encouraging early detection, broadening access to effective antiretroviral therapies, enhancing prevention strategies, and strengthening healthcare systems, all of which contribute to improved control over the virus’s dissemination. For instance, in November 2024, data released by the European Centre for Disease Prevention and Control (ECDC), a Sweden-based European Union agency, revealed that a total of 112,883 HIV diagnoses were reported in 2023 across 47 out of 53 countries in the region, with 24,731 cases recorded specifically in the European Union/European Economic Area (EU/EEA). The overall crude rate of HIV diagnoses reached 12.7 per 100,000 population, representing a 2.4% increase when compared to the 12.4 per 100,000 rates observed in 2022. Thus, the escalating number of HIV infections is a key driver for the acquired immunodeficiency syndrome (AIDS) market.
What Are The Major Segments Identified In The Acquired Immunodeficiency Syndrome (AIDS) Market?
The acquired immunodeficiency syndrome (aids)market covered in this report is segmented –
1) By Type: Human Immunodeficiency Virus 1; Human Immunodeficiency Virus 2
2) By Drug Type: Nucleoside-Analog Reverse Transcriptase Inhibitors; Non-Nucleoside Reverse Transcriptase Inhibitors; Fusion Inhibitors; CCR5 Anatagonists And Post-Attachment Inhibitors; Protease Inhibitors; Integrase Inhibitors; Pre-Exposure Prophylaxis And Post-Exposure Prophylaxis
3) By Route Of Administration: Oral; Parenteral
4) By Application: Hospital Pharmacy; Retail Pharmacy; Other Applications
5) By Distribution Channel: Offline; Online
Subsegments:
1) By Human Immunodeficiency Virus 1 (HIV-1): Antiretroviral Therapy (ART); Pre-Exposure Prophylaxis (PrEP); Post-Exposure Prophylaxis (PEP); HIV-1 Diagnostic Tests; HIV-1 Vaccine Development; HIV-1 Opportunistic Infection Management
2) By Human Immunodeficiency Virus 2 (HIV-2): Antiretroviral Therapy (ART) For HIV-2; HIV-2 Diagnostic Tests; HIV-2 Surveillance And Epidemiology; HIV-2 Vaccine Research; Management Of HIV-2 Co-Infections
What Trends Are Expected To Drive The Acquired Immunodeficiency Syndrome (AIDS) Market?
Leading companies in the acquired immunodeficiency syndrome (AIDS) market are prioritizing the creation of innovative treatments, such as long-acting injectables. These offer enhanced patient adherence, reduce the need for frequent dosing, and present a more convenient option than daily oral antiretroviral treatments. Long-acting injectables are medications delivered via injection, engineered to gradually release their active ingredients over an extended duration, which permits less frequent administration compared to traditional oral drugs. For example, in January 2025, GSK plc., a UK-based pharmaceutical company, declared the European Commission’s approval for its long-acting injectable treatment, Vocabria (cabotegravir) plus Rekambys (rilpivirine). This particular therapy is authorized for use in adolescents aged 12 years and older living with HIV. It is administered through intramuscular injection, typically either monthly or bimonthly, depending on the specific treatment plan. The prolonged effect of these injections has the potential to improve adherence rates among adolescents who encounter difficulties with daily pill regimens.
Which Major Firms Are Strengthening Their Position In The Acquired Immunodeficiency Syndrome (AIDS) Industry?
Major companies operating in the acquired immunodeficiency syndrome (AIDS) market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Abbott, GSK plc, Takeda Pharmaceuticals, Gilead Sciences, Viatris Inc., Teva Pharmaceuticals, Aurobindo Pharma, Cipla Ltd, Shionogi and Co., Dr. Reddy’s Laboratories, Lupin, Hetero Drugs Limited, Glenmark Pharmaceuticals Limited, ViiV Healthcare
Download The Full Report For Exclusive Market Findings:
Which Global Regions Are Influencing The Competitive Landscape Of The Acquired Immunodeficiency Syndrome (AIDS) Market?
North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired immunodeficiency syndrome (AIDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Acquired Immunodeficiency Syndrome (AIDS) Market Report:
https://www.thebusinessresearchcompany.com/customise?id=21076&type=smp
Browse Through More Reports Similar to the Global Acquired Immunodeficiency Syndrome (AIDS) Market 2025, By The Business Research Company
Hiv Drug Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/hiv-drug-global-market-report
Autoimmune Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report
Immune Health Supplements Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/immune-health-supplements-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model